{"name":"Roche","slug":"roche","ticker":"RHHBY","exchange":"OTC","domain":"roche.com","description":"F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. \nRoche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.","hq":"Basel, Switzerland","founded":1896,"employees":"~95,000","ceo":"Thomas Schinecker","sector":"Big Pharma","stockPrice":49.77,"stockChange":-0.21,"stockChangePercent":-0.42,"marketCap":"$320.6B","metrics":{"revenue":63355998208,"revenueGrowth":-0.4,"grossMargin":74.5,"rdSpend":0,"netIncome":12880000000,"cash":15486000128,"dividendYield":3.23,"peRatio":19.8,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Ocrevus","genericName":"OCRELIZUMAB","slug":"ocrelizumab","revenue":6500000000,"yoyGrowth":0,"percentOfTotal":16.2},{"name":"Vabysmo","genericName":"FARICIMAB","slug":"faricimab","revenue":5500000000,"yoyGrowth":0,"percentOfTotal":13.7},{"name":"Hemlibra","genericName":"EMICIZUMAB","slug":"emicizumab","revenue":4800000000,"yoyGrowth":0,"percentOfTotal":12},{"name":"Mabthera","genericName":"rituxan","slug":"rituxan","revenue":3800000000,"yoyGrowth":0,"percentOfTotal":9.5},{"name":"Tecentriq","genericName":"atezolizumab","slug":"atezolizumab","revenue":3700000000,"yoyGrowth":0,"percentOfTotal":9.2},{"name":"Xolair","genericName":"omalizumab","slug":"omalizumab","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":8},{"name":"Herceptin","genericName":"trastuzumab","slug":"trastuzumab","revenue":2900000000,"yoyGrowth":0,"percentOfTotal":7.2},{"name":"Evrysdi","genericName":"RISDIPLAM","slug":"risdiplam","revenue":2300000000,"yoyGrowth":0,"percentOfTotal":5.7},{"name":"Avastin","genericName":"bevacizumab","slug":"bevacizumab","revenue":2100000000,"yoyGrowth":0,"percentOfTotal":5.2},{"name":"Polivy","genericName":"POLATUZUMAB VEDOTIN","slug":"polatuzumab-vedotin","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":4},{"name":"Gazyva","genericName":"obinutuzumab","slug":"obinutuzumab","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":3},{"name":"Kadcyla","genericName":"trastuzumab-emtansine","slug":"trastuzumab-emtansine","revenue":900000000,"yoyGrowth":0,"percentOfTotal":2.2},{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","revenue":700000000,"yoyGrowth":0,"percentOfTotal":1.7},{"name":"Columvi","genericName":"glofitamab","slug":"glofitamab","revenue":300000000,"yoyGrowth":0,"percentOfTotal":0.7},{"name":"Rozlytrek","genericName":"entrectinib","slug":"entrectinib","revenue":300000000,"yoyGrowth":0,"percentOfTotal":0.7},{"name":"Cotellic","genericName":"cobimetinib","slug":"cobimetinib","revenue":200000000,"yoyGrowth":0,"percentOfTotal":0.5},{"name":"Zelboraf","genericName":"vemurafenib","slug":"vemurafenib","revenue":100000000,"yoyGrowth":0,"percentOfTotal":0.2}],"timeline":[{"date":"1953-01-01","label":"Gantrisin first approved","drug":"Gantrisin","drugSlug":"sulfisoxazole-acetyl","type":"approval","sentiment":"positive"},{"date":"1967-01-01","label":"Taractan first approved","drug":"Taractan","drugSlug":"chlorprothixene","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Sodium Nitroprusside first approved","drug":"Sodium Nitroprusside","drugSlug":"nitroprusside","type":"approval","sentiment":"positive"},{"date":"1987-01-01","label":"Ro 205720 first approved","drug":"Ro 205720","drugSlug":"carprofen","type":"approval","sentiment":"positive"},{"date":"1989-01-01","label":"Cytovene first approved","drug":"Cytovene","drugSlug":"ganciclovir","type":"approval","sentiment":"positive"},{"date":"1993-01-01","label":"Pulmozyme first approved","drug":"Pulmozyme","drugSlug":"dornase-alfa","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Cellcept first approved","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Activase first approved","drug":"Activase","drugSlug":"alteplase","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Mabthera first approved","drug":"Mabthera","drugSlug":"rituxan","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Zenapax first approved","drug":"Zenapax","drugSlug":"daclizumab","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Herceptin first approved","drug":"Herceptin","drugSlug":"trastuzumab","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Tnkase first approved","drug":"Tnkase","drugSlug":"tenecteplase","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Boniva first approved","drug":"Boniva","drugSlug":"ibandronic-acid","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Fuzeon first approved","drug":"Fuzeon","drugSlug":"enfuvirtide","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Hu1124 first approved","drug":"Hu1124","drugSlug":"efalizumab","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Avastin first approved","drug":"Avastin","drugSlug":"bevacizumab","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Roactemra first approved","drug":"Roactemra","drugSlug":"tocilizumab","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Zelboraf first approved","drug":"Zelboraf","drugSlug":"vemurafenib","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Erivedge first approved","drug":"Erivedge","drugSlug":"vismodegib","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Gazyva first approved","drug":"Gazyva","drugSlug":"obinutuzumab","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Kadcyla first approved","drug":"Kadcyla","drugSlug":"trastuzumab-emtansine","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Alecensa first approved","drug":"Alecensa","drugSlug":"alectinib","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Cotellic first approved","drug":"Cotellic","drugSlug":"cobimetinib","type":"approval","sentiment":"positive"},{"date":"2016-01-01","label":"Tecentriq first approved","drug":"Tecentriq","drugSlug":"atezolizumab","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Ocrevus first approved","drug":"Ocrevus","drugSlug":"ocrelizumab","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Hemlibra first approved","drug":"Hemlibra","drugSlug":"emicizumab","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Xofluza first approved","drug":"Xofluza","drugSlug":"baloxavir-marboxil","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Polivy first approved","drug":"Polivy","drugSlug":"polatuzumab-vedotin","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Rozlytrek first approved","drug":"Rozlytrek","drugSlug":"entrectinib","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Evrysdi first approved","drug":"Evrysdi","drugSlug":"risdiplam","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Vabysmo first approved","drug":"Vabysmo","drugSlug":"faricimab","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Lunsumio first approved","drug":"Lunsumio","drugSlug":"mosunetuzumab","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Columvi first approved","drug":"Columvi","drugSlug":"glofitamab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Piasky first approved","drug":"Piasky","drugSlug":"crovalimab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Xofluza first approved","drug":"Xofluza","drugSlug":"baloxavir","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Itovebi first approved","drug":"Itovebi","drugSlug":"chembl-chembl4650215","type":"approval","sentiment":"positive"},{"date":"2026-05-14","label":"Rozlytrek PHASE2 readout","drug":"Rozlytrek","drugSlug":"entrectinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-05-29","label":"VABYSMO Phase 3 readout (Choroidal Neovascularization Secondary to Pathologic Myopia)","drug":"VABYSMO","drugSlug":"faricimab-svoa","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"Piasky PHASE3 readout","drug":"Piasky","drugSlug":"crovalimab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-08-31","label":"Tecentriq PHASE3 readout","drug":"Tecentriq","drugSlug":"atezolizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-09-30","label":"Piasky PHASE3 readout","drug":"Piasky","drugSlug":"crovalimab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-15","label":"Itovebi PHASE2,PHASE3 readout","drug":"Itovebi","drugSlug":"chembl-chembl4650215","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-11-30","label":"VABYSMO Phase 3 readout (Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration)","drug":"VABYSMO","drugSlug":"faricimab-svoa","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-12-31","label":"Columvi PHASE1,PHASE2 readout","drug":"Columvi","drugSlug":"glofitamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-31","label":"LUNSUMIO Phase 3 readout (Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features)","drug":"LUNSUMIO","drugSlug":"mosunetuzumab-axgb","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-09-02","label":"Cytovene patent expiry (Formulation)","drug":"Cytovene","drugSlug":"ganciclovir","type":"patent_expiry","sentiment":"negative"},{"date":"2039-08-16","label":"Cellcept patent expiry (Formulation)","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-08-16","label":"Cellcept patent expiry (Formulation)","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-08-16","label":"Cellcept patent expiry (Formulation)","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-08-16","label":"Cellcept patent expiry (Formulation)","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"patent_expiry","sentiment":"negative"},{"date":"2039-08-16","label":"Cellcept patent expiry (Formulation)","drug":"Cellcept","drugSlug":"mycophenolate-mofetil","type":"patent_expiry","sentiment":"negative"},{"date":"2041-04-21","label":"Xofluza patent expiry (Formulation)","drug":"Xofluza","drugSlug":"baloxavir-marboxil","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Ocrevus patent cliff ($2.5B at risk)","drug":"Ocrevus","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Hemlibra patent cliff ($1.5B at risk)","drug":"Hemlibra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":17800000000,"percentOfTotal":44.4,"drugCount":23,"colorKey":"neuroscience","drugs":[{"name":"Mabthera","genericName":"rituxan","slug":"rituxan","indication":"Burkitt cell leukemia","status":"marketed","revenue":3800000000},{"name":"Tecentriq","genericName":"atezolizumab","slug":"atezolizumab","indication":"Extensive stage primary small cell carcinoma of lung","status":"marketed","revenue":3700000000},{"name":"Herceptin","genericName":"trastuzumab","slug":"trastuzumab","indication":"HER2-positive carcinoma of breast","status":"marketed","revenue":2900000000},{"name":"Avastin","genericName":"bevacizumab","slug":"bevacizumab","indication":"Carcinoma of cervix","status":"marketed","revenue":2100000000},{"name":"Polivy","genericName":"POLATUZUMAB VEDOTIN","slug":"polatuzumab-vedotin","indication":"Diffuse large B-cell lymphoma refractory","status":"marketed","revenue":1600000000},{"name":"Gazyva","genericName":"obinutuzumab","slug":"obinutuzumab","indication":"CD20-positive follicular lymphoma","status":"marketed","revenue":1200000000},{"name":"Kadcyla","genericName":"trastuzumab-emtansine","slug":"trastuzumab-emtansine","indication":"Adjuvant treatment of HER2-positive breast cancer","status":"marketed","revenue":900000000},{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","indication":"Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","status":"marketed","revenue":700000000},{"name":"Columvi","genericName":"glofitamab","slug":"glofitamab","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"marketed","revenue":300000000},{"name":"Rozlytrek","genericName":"entrectinib","slug":"entrectinib","indication":"Reactive oxygen species 1 positive non-small cell lung cancer","status":"marketed","revenue":300000000},{"name":"Cotellic","genericName":"cobimetinib","slug":"cobimetinib","indication":"Unresectable or Metastatic Melanoma","status":"marketed","revenue":200000000},{"name":"Zelboraf","genericName":"vemurafenib","slug":"vemurafenib","indication":"Erdheim-Chester Disease","status":"marketed","revenue":100000000},{"name":"Bevacizumab","genericName":"Bevacizumab-Bvzr","slug":"zirabev","indication":"Carcinoma of cervix","status":"marketed"},{"name":"Herceptin","genericName":"Trastuzumab-Qyyp","slug":"trazimera","indication":"HER2-positive carcinoma of breast","status":"marketed"},{"name":"Mabthera","genericName":"Rituximab-Pvvr","slug":"ruxience","indication":"Burkitt cell leukemia","status":"marketed"},{"name":"Perjeta","genericName":"pertuzumab","slug":"pertuzumab","indication":"HER2-positive carcinoma of breast","status":"marketed"},{"name":"Mabthera","genericName":"rituximab","slug":"rituximab","indication":"Burkitt cell leukemia","status":"marketed"},{"name":"Erivedge","genericName":"vismodegib","slug":"vismodegib","indication":"Basal cell carcinoma of skin","status":"marketed"},{"name":"Neorecormon","genericName":"EPOETIN BETA","slug":"epoetin-beta","indication":"Anemia due to chemotherapy for nonmyeloid cancer","status":"marketed"},{"name":"COLUMVI","genericName":"GLOFITAMAB-GXBM","slug":"glofitamab-gxbm","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"marketed"},{"name":"Itovebi","genericName":"INAVOLISIB","slug":"chembl-chembl4650215","indication":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","status":"marketed"},{"name":"LUNSUMIO","genericName":"MOSUNETUZUMAB-AXGB","slug":"mosunetuzumab-axgb","indication":"Relapsed or refractory follicular lymphoma","status":"marketed"},{"name":"Lunsumio","genericName":"MOSUNETUZUMAB","slug":"mosunetuzumab","indication":"Relapsed or refractory follicular lymphoma","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":8800000000,"percentOfTotal":21.9,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Ocrevus","genericName":"OCRELIZUMAB","slug":"ocrelizumab","indication":"Primary progressive multiple sclerosis","status":"marketed","revenue":6500000000},{"name":"Evrysdi","genericName":"RISDIPLAM","slug":"risdiplam","indication":"Spinal muscular atrophy","status":"marketed","revenue":2300000000},{"name":"Dyanavel XR","genericName":"Dyanavel XR","slug":"dyanavel-xr","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"marketed"},{"name":"Taractan","genericName":"CHLORPROTHIXENE","slug":"chlorprothixene","indication":"Schizophrenia","status":"marketed"},{"name":"Zenapax","genericName":"DACLIZUMAB","slug":"daclizumab","indication":"Relapsing remitting multiple sclerosis","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":5500000000,"percentOfTotal":13.7,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Vabysmo","genericName":"FARICIMAB","slug":"faricimab","indication":"Exudative age-related macular degeneration","status":"marketed","revenue":5500000000},{"name":"VABYSMO","genericName":"FARICIMAB-SVOA","slug":"faricimab-svoa","indication":"Exudative age-related macular degeneration","status":"marketed"}]},{"name":"Other","slug":"other","revenue":4800000000,"percentOfTotal":12,"drugCount":16,"colorKey":"cardiovascular","drugs":[{"name":"Hemlibra","genericName":"EMICIZUMAB","slug":"emicizumab","indication":"Hereditary factor VIII deficiency disease","status":"marketed","revenue":4800000000},{"name":"LTRA","genericName":"LTRA","slug":"ltra","indication":"Other","status":"marketed"},{"name":"Noctan","genericName":"METHYPRYLON","slug":"methyprylon","indication":"Insomnia","status":"marketed"},{"name":"Piasky","genericName":"CROVALIMAB","slug":"crovalimab","indication":"paroxysmal nocturnal hemoglobinuria (PNH)","status":"marketed"},{"name":"Ro 205720","genericName":"CARPROFEN","slug":"carprofen","indication":"Other","status":"marketed"},{"name":"Xofluza","genericName":"BALOXAVIR","slug":"baloxavir","indication":"Treatment of acute uncomplicated influenza","status":"marketed"},{"name":"Activase","genericName":"ALTEPLASE","slug":"alteplase","indication":"Restoration of function to central venous access devices","status":"marketed"},{"name":"Boniva","genericName":"IBANDRONIC ACID","slug":"ibandronic-acid","indication":"Hypercalcemia","status":"marketed"},{"name":"Gantrisin","genericName":"SULFISOXAZOLE ACETYL","slug":"sulfisoxazole-acetyl","indication":"Other","status":"marketed"},{"name":"Hexapen","genericName":"Mecillinam","slug":"mecillinam","indication":"Other","status":"marketed"},{"name":"PIASKY","genericName":"CROVALIMAB-AKKZ","slug":"crovalimab-akkz","indication":"Other","status":"marketed"},{"name":"Placebo \"30, 50 or 70 mg\"","genericName":"Placebo \"30, 50 or 70 mg\"","slug":"placebo-30-50-or-70-mg","indication":"Research and clinical trial control comparator","status":"marketed"},{"name":"Pulmozyme","genericName":"DORNASE ALFA","slug":"dornase-alfa","indication":"Cystic fibrosis","status":"marketed"},{"name":"Solriamfetol Oral Tablet [Sunosi]","genericName":"Solriamfetol Oral Tablet [Sunosi]","slug":"solriamfetol-oral-tablet-sunosi","indication":"Excessive daytime sleepiness in patients with narcolepsy","status":"marketed"},{"name":"Tnkase","genericName":"TENECTEPLASE","slug":"tenecteplase","indication":"Acute myocardial infarction","status":"marketed"},{"name":"Xofluza","genericName":"BALOXAVIR MARBOXIL","slug":"baloxavir-marboxil","indication":"Influenza","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":3200000000,"percentOfTotal":8,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Xolair","genericName":"omalizumab","slug":"omalizumab","indication":"Asthma","status":"marketed","revenue":3200000000}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"respiratory","drugs":[{"name":"Roactemra","genericName":"tocilizumab","slug":"tocilizumab","indication":"Rheumatoid Arthritis (RA)","status":"marketed"},{"name":"Cellcept","genericName":"MYCOPHENOLATE MOFETIL","slug":"mycophenolate-mofetil","indication":"Prevention of Cardiac Transplant Rejection","status":"marketed"},{"name":"Cytovene","genericName":"GANCICLOVIR","slug":"ganciclovir","indication":"CMV Retinitis in AIDS Patients","status":"marketed"},{"name":"Fuzeon","genericName":"ENFUVIRTIDE","slug":"enfuvirtide","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Hu1124","genericName":"EFALIZUMAB","slug":"efalizumab","indication":"Plaque psoriasis","status":"marketed"},{"name":"Librax","genericName":"CLIDINIUM","slug":"clidinium","indication":"Enterocolitis","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Lorfan","genericName":"LEVALLORPHAN","slug":"levallorphan","indication":"Rare Disease","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Sodium Nitroprusside","genericName":"NITROPRUSSIDE","slug":"nitroprusside","indication":"Acute exacerbation of chronic congestive heart failure","status":"marketed"}]}],"pipeline":[{"name":"Ocrevus","genericName":"OCRELIZUMAB","slug":"ocrelizumab","phase":"marketed","mechanism":"Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process.","indications":["Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Vabysmo","genericName":"FARICIMAB","slug":"faricimab","phase":"marketed","mechanism":"Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A.","indications":["Exudative age-related macular degeneration","Macular edema due to diabetes mellitus"],"catalyst":""},{"name":"Hemlibra","genericName":"EMICIZUMAB","slug":"emicizumab","phase":"marketed","mechanism":"Hemlibra works by binding to and activating factor IXa, a protein involved in blood clotting, to bypass the need for factor VIII.","indications":["Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Mabthera","genericName":"rituxan","slug":"rituxan","phase":"marketed","mechanism":"B-lymphocyte antigen CD20","indications":["Burkitt cell leukemia","Burkitt's lymphoma","CD20 positive diffuse large B cell non Hodgkin's lymphoma","Chronic lymphoid leukemia, disease","Follicular lymphoma"],"catalyst":""},{"name":"Tecentriq","genericName":"atezolizumab","slug":"atezolizumab","phase":"marketed","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.","indications":["Extensive stage primary small cell carcinoma of lung","Germline BRCA-mutated, HER2-negative metastatic breast cancer","Liver cell carcinoma","Metastatic non-small cell lung cancer","Transitional cell carcinoma"],"catalyst":""},{"name":"Xolair","genericName":"omalizumab","slug":"omalizumab","phase":"marketed","mechanism":"Ig epsilon chain C region","indications":["Asthma","Chronic idiopathic urticaria","Seasonal allergic rhinitis"],"catalyst":""},{"name":"Herceptin","genericName":"trastuzumab","slug":"trastuzumab","phase":"marketed","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells.","indications":["HER2-positive carcinoma of breast","HER2-positive colon cancer","HER2-positive rectal cancer","HER2-positive salivary gland tumors","Human epidermal growth factor 2 positive gastric cancer"],"catalyst":""},{"name":"Evrysdi","genericName":"RISDIPLAM","slug":"risdiplam","phase":"marketed","mechanism":"Evrysdi works by increasing the production of survival motor neuron protein.","indications":["Spinal muscular atrophy"],"catalyst":""},{"name":"Avastin","genericName":"bevacizumab","slug":"bevacizumab","phase":"marketed","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.","indications":["Carcinoma of cervix","Glioblastoma multiforme","Liver cell carcinoma","Malignant epithelial tumor of ovary","Malignant neoplasm of breast"],"catalyst":""},{"name":"Polivy","genericName":"POLATUZUMAB VEDOTIN","slug":"polatuzumab-vedotin","phase":"marketed","mechanism":"Polivy works by binding to a protein on the surface of cancer cells and releasing a toxin that kills the cell.","indications":["Diffuse large B-cell lymphoma refractory"],"catalyst":""},{"name":"Gazyva","genericName":"obinutuzumab","slug":"obinutuzumab","phase":"marketed","mechanism":"Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction.","indications":["CD20-positive follicular lymphoma","Chronic lymphoid leukemia, disease"],"catalyst":""},{"name":"Kadcyla","genericName":"trastuzumab-emtansine","slug":"trastuzumab-emtansine","phase":"marketed","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent.","indications":["Adjuvant treatment of HER2-positive breast cancer","Treatment of HER2-positive breast cancer in patients who have received prior trastuzumab-based therapy","Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated","Treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2-based therapy"],"catalyst":""},{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","phase":"marketed","mechanism":"Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.","indications":["Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","Non-small cell lung cancer"],"catalyst":""},{"name":"Columvi","genericName":"glofitamab","slug":"glofitamab","phase":"marketed","mechanism":"Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells.","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Rozlytrek","genericName":"entrectinib","slug":"entrectinib","phase":"marketed","mechanism":"Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor.","indications":["Reactive oxygen species 1 positive non-small cell lung cancer","Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion"],"catalyst":""},{"name":"Cotellic","genericName":"cobimetinib","slug":"cobimetinib","phase":"marketed","mechanism":"Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells.","indications":["Unresectable or Metastatic Melanoma","Histiocytic Neoplasms"],"catalyst":""},{"name":"Zelboraf","genericName":"vemurafenib","slug":"vemurafenib","phase":"marketed","mechanism":"Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division.","indications":["Erdheim-Chester Disease","Malignant Melanoma with BRAF V600E Mutation"],"catalyst":""},{"name":"Bevacizumab","genericName":"Bevacizumab-Bvzr","slug":"zirabev","phase":"marketed","mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR.","indications":["Carcinoma of cervix","Glioblastoma multiforme","Liver cell carcinoma","Malignant epithelial tumor of ovary","Malignant neoplasm of breast"],"catalyst":""},{"name":"Herceptin","genericName":"Trastuzumab-Qyyp","slug":"trazimera","phase":"marketed","mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity.","indications":["HER2-positive carcinoma of breast","HER2-positive colon cancer","HER2-positive rectal cancer","HER2-positive salivary gland tumors","Human epidermal growth factor 2 positive gastric cancer"],"catalyst":""},{"name":"Mabthera","genericName":"Rituximab-Pvvr","slug":"ruxience","phase":"marketed","mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC.","indications":["Burkitt cell leukemia","Burkitt's lymphoma","CD20 positive diffuse large B cell non Hodgkin's lymphoma","Chronic lymphoid leukemia, disease","Follicular lymphoma"],"catalyst":""},{"name":"Perjeta","genericName":"pertuzumab","slug":"pertuzumab","phase":"marketed","mechanism":"Pertuzumab targets the extracellular dimerization domain of the HER2 protein, blocking ligand-dependent heterodimerization with other HER family members.","indications":["HER2-positive carcinoma of breast","HER2-positive colon cancer","HER2-positive rectal cancer"],"catalyst":""},{"name":"Mabthera","genericName":"rituximab","slug":"rituximab","phase":"marketed","mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.","indications":["Burkitt cell leukemia","Burkitt's lymphoma","CD20 positive diffuse large B cell non Hodgkin's lymphoma","Chronic lymphoid leukemia, disease","Follicular lymphoma"],"catalyst":""},{"name":"Erivedge","genericName":"vismodegib","slug":"vismodegib","phase":"marketed","mechanism":"Vismodegib inhibits the Hedgehog pathway by binding to and blocking Smoothened, a key protein in the pathway.","indications":["Basal cell carcinoma of skin"],"catalyst":""},{"name":"Roactemra","genericName":"tocilizumab","slug":"tocilizumab","phase":"marketed","mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation.","indications":["Rheumatoid Arthritis (RA)","Giant Cell Arteritis (GCA)","Polyarticular Juvenile Idiopathic Arthritis (PJIA)","Systemic Juvenile Idiopathic Arthritis (SJIA)","Coronavirus Disease 2019 (COVID-19)"],"catalyst":""},{"name":"LTRA","genericName":"LTRA","slug":"ltra","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Neorecormon","genericName":"EPOETIN BETA","slug":"epoetin-beta","phase":"marketed","mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production.","indications":["Anemia due to chemotherapy for nonmyeloid cancer","Anemia in chronic kidney disease","Prevention of anaemia in premature babies"],"catalyst":""},{"name":"Noctan","genericName":"METHYPRYLON","slug":"methyprylon","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-3/gamma-2","indications":["Insomnia"],"catalyst":""},{"name":"Piasky","genericName":"CROVALIMAB","slug":"crovalimab","phase":"marketed","mechanism":"Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances.","indications":["paroxysmal nocturnal hemoglobinuria (PNH)"],"catalyst":""},{"name":"Ro 205720","genericName":"CARPROFEN","slug":"carprofen","phase":"marketed","mechanism":"Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","indications":[],"catalyst":""},{"name":"Xofluza","genericName":"BALOXAVIR","slug":"baloxavir","phase":"marketed","mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating.","indications":["Treatment of acute uncomplicated influenza","Post-exposure prophylaxis of influenza","Treatment of Influenza","Post-Exposure Prophylaxis of Influenza"],"catalyst":""},{"name":"Activase","genericName":"ALTEPLASE","slug":"alteplase","phase":"marketed","mechanism":"Plasminogen","indications":["Restoration of function to central venous access devices"],"catalyst":""},{"name":"Boniva","genericName":"IBANDRONIC ACID","slug":"ibandronic-acid","phase":"marketed","mechanism":"Farnesyl pyrophosphate synthase","indications":["Hypercalcemia","Postmenopausal osteoporosis"],"catalyst":""},{"name":"COLUMVI","genericName":"GLOFITAMAB-GXBM","slug":"glofitamab-gxbm","phase":"marketed","mechanism":"B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3 epsilon chain","indications":["Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Cellcept","genericName":"MYCOPHENOLATE MOFETIL","slug":"mycophenolate-mofetil","phase":"marketed","mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides.","indications":["Prevention of Cardiac Transplant Rejection","Prevention of Kidney Transplant Rejection","Prevention of Liver Transplant Rejection","The suppression of graft-versus-host disease in hematopoietic stem cell transplantation"],"catalyst":""},{"name":"Cytovene","genericName":"GANCICLOVIR","slug":"ganciclovir","phase":"marketed","mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication.","indications":["CMV Retinitis in AIDS Patients","CMV Retinitis in Immunocompromised Patients","Cytomegaloviral retinitis","Herpes simplex dendritic keratitis","Myocardial Perfusion Imaging Adjunct"],"catalyst":""},{"name":"Dyanavel XR","genericName":"Dyanavel XR","slug":"dyanavel-xr","phase":"marketed","mechanism":"Dyanavel XR is an extended-release liquid formulation of amphetamine that increases the release of dopamine and norepinephrine in the central nervous system to improve attention and reduce hyperactivity.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""},{"name":"Fuzeon","genericName":"ENFUVIRTIDE","slug":"enfuvirtide","phase":"marketed","mechanism":"Recombinant protein","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Gantrisin","genericName":"SULFISOXAZOLE ACETYL","slug":"sulfisoxazole-acetyl","phase":"marketed","mechanism":"Endothelin B receptor, Endothelin-1 receptor, Dihydropteroate synthase","indications":[],"catalyst":""},{"name":"Hexapen","genericName":"Mecillinam","slug":"mecillinam","phase":"marketed","mechanism":"Hexapen works by inhibiting bacterial cell wall synthesis, preventing the bacteria from producing a strong cell wall.","indications":[],"catalyst":""},{"name":"Hu1124","genericName":"EFALIZUMAB","slug":"efalizumab","phase":"marketed","mechanism":"Leukocyte adhesion glycoprotein LFA-1 alpha","indications":["Plaque psoriasis"],"catalyst":""},{"name":"Itovebi","genericName":"INAVOLISIB","slug":"chembl-chembl4650215","phase":"marketed","mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells.","indications":["endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer"],"catalyst":""},{"name":"LUNSUMIO","genericName":"MOSUNETUZUMAB-AXGB","slug":"mosunetuzumab-axgb","phase":"marketed","mechanism":"B-lymphocyte antigen CD20","indications":["Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"Librax","genericName":"CLIDINIUM","slug":"clidinium","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M3","indications":["Enterocolitis","Irritable bowel syndrome"],"catalyst":""},{"name":"Lorfan","genericName":"LEVALLORPHAN","slug":"levallorphan","phase":"marketed","mechanism":"Mu-type opioid receptor, Acetylcholinesterase, Mu-type opioid receptor","indications":[],"catalyst":""},{"name":"Lunsumio","genericName":"MOSUNETUZUMAB","slug":"mosunetuzumab","phase":"marketed","mechanism":"Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.","indications":["Relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"PIASKY","genericName":"CROVALIMAB-AKKZ","slug":"crovalimab-akkz","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Placebo \"30, 50 or 70 mg\"","genericName":"Placebo \"30, 50 or 70 mg\"","slug":"placebo-30-50-or-70-mg","phase":"marketed","mechanism":"Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous neurobiological pathways independent of pharmacological action.","indications":["Research and clinical trial control comparator"],"catalyst":""},{"name":"Pulmozyme","genericName":"DORNASE ALFA","slug":"dornase-alfa","phase":"marketed","mechanism":"Pulmozyme breaks down DNA in the airways to reduce mucus viscosity.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Sodium Nitroprusside","genericName":"NITROPRUSSIDE","slug":"nitroprusside","phase":"marketed","mechanism":"Atrial natriuretic peptide receptor 1","indications":["Acute exacerbation of chronic congestive heart failure","Acute heart failure","Controlled Hypotension","Decompensated cardiac failure","Hypertensive disorder"],"catalyst":""},{"name":"Solriamfetol Oral Tablet [Sunosi]","genericName":"Solriamfetol Oral Tablet [Sunosi]","slug":"solriamfetol-oral-tablet-sunosi","phase":"marketed","mechanism":"Solriamfetol is a dopamine and norepinephrine reuptake inhibitor that increases wakefulness by blocking the reuptake of these neurotransmitters in the central nervous system.","indications":["Excessive daytime sleepiness in patients with narcolepsy","Excessive daytime sleepiness in patients with obstructive sleep apnea"],"catalyst":""},{"name":"Taractan","genericName":"CHLORPROTHIXENE","slug":"chlorprothixene","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2A","indications":["Schizophrenia"],"catalyst":""},{"name":"Tnkase","genericName":"TENECTEPLASE","slug":"tenecteplase","phase":"marketed","mechanism":"Tenecteplase binds to fibrin and converts plasminogen to plasmin, enhancing fibrin-specific plasmin generation.","indications":["Acute myocardial infarction","Ankylosing spondylitis"],"catalyst":""},{"name":"VABYSMO","genericName":"FARICIMAB-SVOA","slug":"faricimab-svoa","phase":"marketed","mechanism":"Angiopoietin-2, Vascular endothelial growth factor A","indications":["Exudative age-related macular degeneration","Macular edema due to diabetes mellitus"],"catalyst":""},{"name":"Xofluza","genericName":"BALOXAVIR MARBOXIL","slug":"baloxavir-marboxil","phase":"marketed","mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus's polymerase, preventing viral replication.","indications":["Influenza"],"catalyst":""},{"name":"Zenapax","genericName":"DACLIZUMAB","slug":"daclizumab","phase":"marketed","mechanism":"Interleukin-2 receptor","indications":["Relapsing remitting multiple sclerosis","Renal transplant rejection"],"catalyst":""}],"recentEvents":[{"date":"2023-02-02","type":"earnings","headline":"Roche reports strong Q4 2022 results, beats expectations","summary":"Roche reported strong Q4 2022 results, with revenue up 10% year-over-year and adjusted EPS of CHF 2.85. The company's strong performance was driven by the success of its key products, including Polivy and Ocrevus.","drugName":"","sentiment":"positive"},{"date":"2022-06-17","type":"regulatory","headline":"FDA approves Roche's Polivy for treatment of diffuse large B-cell lymphoma","summary":"The US FDA has approved Roche's Polivy (polatuzumab vedotin-piiq) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.","drugName":"","sentiment":"positive"},{"date":"2021-03-19","type":"deal","headline":"Roche acquires Spark Therapeutics for $4.8 billion","summary":"Roche has acquired Spark Therapeutics, a gene therapy company, for $4.8 billion. The acquisition is expected to strengthen Roche's presence in the gene therapy market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNZG00YVBSamVVMmFvM1V3V01lT285a09jUHdBMUFhNjV1bm9wX0NCRVNlS0p5eVB1Ul91YTUzSVp1MTkwaGtZV0hxTjNFYXdUZ2lIcnBUX1Z1QkhET2RCYnRHYndVRWZLTmxKUXR6dE1Mb19YZHFqUkEwRDhwVWIxTjc3NDFWRFVEV1E?oc=5","date":"2026-03-16","type":"pipeline","source":"AASTOCKS.com","summary":"Roche Adds 2,176 NVIDIA Blackwell GPUs to Build Largest AI Factory in Pharma Industry - AASTOCKS.com","headline":"Roche Adds 2,176 NVIDIA Blackwell GPUs to Build Largest AI Factory in Pharma Industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPVG1HMThMUDBjYkR2cER1OUhNTlAzdS1GRGx6ckx0VktuTDdwWmVyV1dTcmFGM0hiSHZ3a004V3A2R0xDVmlPb3JDdXJfTmpwTlk5M3B4NkhDYUhVZkJBUEdCTVh5SjdxdERMa21XWXVoanBPUkRJTnJUR0JCOXlFS2dxbjlNanNZUE15SFlrckROMVd1dXFvU28zLVoxSXVOU0hnRU9TdTBJcVV0TGc?oc=5","date":"2026-03-05","type":"trial","source":"GuruFocus","summary":"Roche's (RHHBY) Genentech Reports Positive Trial Results for Obe - GuruFocus","headline":"Roche's (RHHBY) Genentech Reports Positive Trial Results for Obe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPVDVFelh5TnliQnFXT2JNdlZkNGJDRUhFbm5WNzNlU3lrd3prMkFDbWlNQ0FWZGhmODNoamNuWS1hOXI1cVlFUDJ4WEtYZC1DWHdRWV9UWGdUbnBfNXM0d1NHeE1PS1NHYzRFZXhRQ2NzUnBTNF9Wc0R4NE5Rd05fR2ZHYWE1cndVS25GaUFQNGdZQXZ0bWd1Sl9PTkNYUExPOUhnV3pIdw?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Prize-winning cancer doctor to steer Roche early drug research - Stock Titan","headline":"Prize-winning cancer doctor to steer Roche early drug research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOVXNXTHpoSEFXTVlyY1MtYkN3eGRNQml4MGpNOG5RSUtlV04zREozbzNNVlBoaWYxQmFQT2xvaTY4Y043eFJPazFQVjdSZTYyX1VoWkM4UmtSNjNGU0R1ZENpbENWUGM5UTNoRUZ4OFhITk9XWGtKTUROUEs4UGhlR0ZzN0dLMUZTRDlLU0FB?oc=5","date":"2026-01-29","type":"pipeline","source":"Seeking Alpha","summary":"Roche's annual results hit by currency headwinds (RHHBY:OTCMKTS) - Seeking Alpha","headline":"Roche's annual results hit by currency headwinds (RHHBY:OTCMKTS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPbWQyWGRXa1NNSTMxUGVFVW5FR2QzVE5yWHVQRkotUm9nODNtNkkzbWc5SEJqdkM2eGdkQ1JLSXgySzdORU1VRmRWQ3RRLWtYWjJlMVFWRFlVOHpzbWljYnp6VWFvNHBYSF93TUZFVHQ5TVZiN2ZQMVU1ZzFwRHZxNzk5S1VtbWFURF9kNHB1SGdqLWpTeThKZVVyamtnQjBiY3lSV3dUQTZycjEyTHpYVHlWSlhNN3lOMlgyYkZMeG44MURVUThLVGdDdmRueW5HZkpaUnk3ZkZ5SEQ5RmxXUlREQWEwSlYy?oc=5","date":"2026-01-21","type":"pipeline","source":"The Globe and Mail","summary":"Roche's Genentech Expands Investment in North Carolina Facility to $2B - The Globe and Mail","headline":"Roche's Genentech Expands Investment in North Carolina Facility to $2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUXBMUVkwV1BiWEs5Ml9tOEhUWk5uYVk3VW1LTnBaR20yUzlmZWRJaVlsS21rQW9XMVEwVS10bEppOGJ1OGNzcFpldlNWcEFaWkxrbmp6SFU0YXJGRlh0UmVZUmFzZ2pYYXZIaFpWeUw5cU9LZHJObGNxb2hDazh4MVN1bkZId2UxX29EekczdV8zZzJ3dDYyQUZsdm1VMkNWUVc4T2hVU0kzTEtR?oc=5","date":"2025-12-10","type":"regulatory","source":"GuruFocus","summary":"Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus","headline":"Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOdGh3UFdGUnhjQjg0V0t6X0dxenZKX2hsbkJuak5landJN2x5RnRqU1lncXNVdzVONWtEM094TFhtNG9kVFNCYzFLR3RpWTRUOTNiME92dHMyQjQyUWpoVjVJSDk2cXd1djhoX3NaX0MyelBwMEFuSUg3UWx0TkdSTkRncEx6VlJaU2FYaDU2M3VyNFNuQWQwOXJic1p3bk40dTdJSWJnd0Q1QmlDWWVZTjB0MkpkVjNURjZSVQ?oc=5","date":"2025-11-30","type":"trial","source":"Seeking Alpha","summary":"Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY) - Seeking Alpha","headline":"Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQWVllTzg0SGFtOHZoV1podUt3YUgwOGNfY1I4Zml3dFBydGhBLTNULUhENHlnbWViWUxJajJpWER3UDZRVS1NcWVfVjN1aDhvVXFrTW9OY0FTc2ZCamJ2alZNUXNsYVNieHFHYjVWUkNTMG5HcG1ZWkVLWG1YU1lFX2dlWm41NTU1Z1F0MEtTaHdFMkd5THVlT1hjWnphd2hpYlc5N1ByVkVtU21UZ0h1bmk0MDU5b1pHc3c?oc=5","date":"2025-11-18","type":"trial","source":"Investor's Business Daily","summary":"Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily","headline":"Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVjZSSE1sN20yaGhCUlMwRUw2Q1c3dlNtMWIyNXE2ZUVvcFJPalNONmgtX2cwd2s2OGlUTjZVUEFHQmJIUEdiMkdvZTBNbkg1UV9SY2dZVEFHQVBhQ0xaTldfQzItcEdSRUtoTzN6RURpTGtIUXB3ay1LNmJYVHZib0hIWDFZdjBYSEUySk5hb0ZzNHJCRVpCUWF3T0tCcHhWd2lfTmxPanBqTlNSRzIwaDBnYURTODdVTkY4?oc=5","date":"2025-11-18","type":"regulatory","source":"Benzinga","summary":"Why Is Olema Pharmaceuticals Stock Soaring Today? - Olema Pharmaceuticals (NASDAQ:OLMA), Roche Holding (O - Benzinga","headline":"Why Is Olema Pharmaceuticals Stock Soaring Today? - Olema Pharmaceuticals (NASDAQ:OLMA), Roche Holding (O","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPN2F1MzJYZnVJU2hlZVZfTDhUWlROaGJicWI4d2s4c21GMWZsVEJURGg2Qi1RWEhtMmJvN3c1c3poUXBwS3JEdkhBVDhYa3JoX3NJMHdnUmwwUE1TTF9qdHFHZkNTaHlfb0J5REZiT1lRYWRpUm03SGVhSElKc2VOZUtPWQ?oc=5","date":"2025-10-23","type":"pipeline","source":"Seeking Alpha","summary":"Roche stock slips despite guidance hike (RHHBY:OTCMKTS) - Seeking Alpha","headline":"Roche stock slips despite guidance hike (RHHBY:OTCMKTS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQUVJxODBlZ3BFSkZUclhoMlFlOWFfWTdBQmNGQUxSY21VeXpYRjhiRXlsMHBWbVQ2aDFldUhfRjlNVmFzeXdMTjU1YUVQaV9JWHJweDF6bGN4YllYaTZpelFIejlvYkd0NzNMZUwybUJZZDBQbnExRHAySDhSeG1NVG4zN21RcE1uS3RzUEtBVml3NU54?oc=5","date":"2025-04-22","type":"pipeline","source":"MedCity News","summary":"Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom - MedCity News","headline":"Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZG1Ib3o0Z3c0eGtCQVFnTjQtNTdlT2lDZ0dqQjJUeHhfclhMWTFXTFZTcmFRRG5hVGxWWmtQLVQzREZIZnNzZEl5aWQ3ZzRHeDVSamhwSVNwQnBKM2lTT3Bxdkszd0JnVFIyeHZjX0xqMG9wUXRTY21SYWZiZTRwNERfUE56UWJsSTNiYXNKRFFrQjVEOGlMMUREbmR6X09EbmlzRNIBqgFBVV95cUxNZXVEQk1CNnUwMnFFdDhQSl9wZDlFQndXQjBRd2ZDa21aSXFNMmZFbU1sWXJCVi1wUzFlMEFNd01idGlEYlc1UUJkX1piQnlfUjhnMWdNZ0thR2RJM20tRmJMWWl4Q25CaExEeVB0RF80S05wZVZ3TS1WZ1dBSnFqdXR1SEVwVnhEYkNXeXNTOXhEYnhlSnI0Vl83ZUtqVURWdXZneVBfUm9tZw?oc=5","date":"2025-03-12","type":"deal","source":"cnbc.com","summary":"Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma - cnbc.com","headline":"Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma","sentiment":"neutral"}],"patents":[{"drugName":"Ocrevus","drugSlug":"ocrelizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Hemlibra","drugSlug":"emicizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Cytovene","drugSlug":"ganciclovir","patentNumber":"9486530","type":"Formulation","expiryDate":"2034-09-02","territory":"US","genericFilings":[]},{"drugName":"Cellcept","drugSlug":"mycophenolate-mofetil","patentNumber":"12194143","type":"Formulation","expiryDate":"2039-08-16","territory":"US","genericFilings":[]},{"drugName":"Cellcept","drugSlug":"mycophenolate-mofetil","patentNumber":"12097285","type":"Formulation","expiryDate":"2039-08-16","territory":"US","genericFilings":[]},{"drugName":"Cellcept","drugSlug":"mycophenolate-mofetil","patentNumber":"12226526","type":"Formulation","expiryDate":"2039-08-16","territory":"US","genericFilings":[]},{"drugName":"Cellcept","drugSlug":"mycophenolate-mofetil","patentNumber":"11931455","type":"Formulation","expiryDate":"2039-08-16","territory":"US","genericFilings":[]},{"drugName":"Cellcept","drugSlug":"mycophenolate-mofetil","patentNumber":"12097284","type":"Formulation","expiryDate":"2039-08-16","territory":"US","genericFilings":[]},{"drugName":"Xofluza","drugSlug":"baloxavir-marboxil","patentNumber":"11925648","type":"Formulation","expiryDate":"2041-04-21","territory":"US","genericFilings":[]}],"drugCount":55,"phaseCounts":{"marketed":55},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co","Bristol-Myers Squibb"],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":49.77,"previousClose":49.98,"fiftyTwoWeekHigh":60.85,"fiftyTwoWeekLow":34.75,"fiftyTwoWeekRange":"34.75 - 60.85","fiftyDayAverage":54.66,"twoHundredDayAverage":46.84,"beta":0.33,"enterpriseValue":61052731392,"forwardPE":15.1,"priceToBook":0.93,"priceToSales":5.06,"enterpriseToRevenue":0.96,"enterpriseToEbitda":2.54,"pegRatio":0.82,"ebitda":24043999232,"ebitdaMargin":38,"freeCashflow":11027874816,"operatingCashflow":18851999744,"totalDebt":33197000704,"debtToEquity":87.6,"currentRatio":1.38,"returnOnAssets":12.9,"returnOnEquity":37.3,"analystRating":"2.4 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":54.77,"targetHighPrice":61.6,"targetLowPrice":46,"dividendRate":1.59,"payoutRatio":0.61,"fiveYearAvgDividendYield":3.21,"exDividendDate":1773360000,"insiderHeldPercent":0,"institutionHeldPercent":0.8,"sharesOutstanding":5511413096,"floatShares":726032918,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.51,"epsForward":3.3,"revenuePerShare":9.95,"bookValue":53.25,"officers":[{"age":58,"name":"Dr. Severin  Schwan Ph.D.","title":"Executive Chairman"},{"age":50,"name":"Dr. Thomas  Schinecker","title":"Group Chief Executive Officer"},{"age":58,"name":"Dr. Alan  Hippe","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Bruno  Eschli","title":"Head of Investor Relations"},{"age":61,"name":"Ms. Claudia  Bockstiegel","title":"General Counsel"},{"age":52,"name":"Ms. Pascale  Schmidt","title":"Chief Compliance Officer"},{"age":50,"name":"Dr. Nina  Schwab-Hautzinger","title":"Head of Group Communications"},{"age":58,"name":"Ms. Maria Cristina A. Wilbur","title":"Chief People Officer"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.roche.com","phone":"41 61 688 88 80"}}